# PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

Study · id `cardio:ct-nct01581073` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01581073](<https://clinicaltrials.gov/study/NCT01581073>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01581073

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

## Technical summary

Registry record NCT01581073. Randomized; no masking; primary purpose treatment. Start 2012-02-16 (actual); primary completion 2017-12-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 476 participants (enrolled count; ClinicalTrials.gov record NCT01581073, source copy `cardio:ctgov-nct01581073-2018-04-18`, retrieved 2026-10-26)
- Started: 2012-02-16 (actual) (ClinicalTrials.gov record NCT01581073, source copy `cardio:ctgov-nct01581073-2018-04-18`, retrieved 2026-10-26)
- Primary completion: 2017-12-07 (actual) (ClinicalTrials.gov record NCT01581073, source copy `cardio:ctgov-nct01581073-2018-04-18`, retrieved 2026-10-26)
- Completion: 2017-12-07 (actual) (ClinicalTrials.gov record NCT01581073, source copy `cardio:ctgov-nct01581073-2018-04-18`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01581073, source copy `cardio:ctgov-nct01581073-2018-04-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01581073-2018-04-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
- Acronym: PREDICT
- Condition: Chronic Kidney Disease
- Condition: Diabetes
- Intervention (Drug): Darbepoetin alfa
- Lead sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Lead sponsor class: OTHER
- Collaborator: Showa University School of Medicine
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (`cardio:org-translational-research-center-for-medical-innovation-kobe-84b340`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial (`cardio:pubmed-32245781`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial (`cardio:pubmed-37289335`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2d2ca93bc4b0d24e949c7b9ab8af85e2976e36e30ea1dff3c4ada06a7a7eb04e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
